The Drugs Controller General of India has approved Itolizumab for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress syndrome. Drugs Controller General of India has approved Itolizumab injection for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome in patients due to COVID-19. After satisfactory result from clinical trials, the drug was approved. Itolizumab injection is already an approved drug of Biocon Limited used for the treatment of patients with active moderate to severe psoriasis.
